Esperion Therapeutics Inc (NASDAQ: ESPR)’s stock price has plunge by 1.60relation to previous closing price of 1.87. Nevertheless, the company has seen a 6.15% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-18 that ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.
Is It Worth Investing in Esperion Therapeutics Inc (NASDAQ: ESPR) Right Now?
Company’s 36-month beta value is 1.04.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ESPR is 195.04M, and currently, short sellers hold a 16.02% ratio of that floaft. The average trading volume of ESPR on February 20, 2025 was 5.78M shares.
ESPR’s Market Performance
ESPR’s stock has seen a 6.15% increase for the week, with a -14.03% drop in the past month and a -9.52% fall in the past quarter. The volatility ratio for the week is 4.68%, and the volatility levels for the past 30 days are at 6.13% for Esperion Therapeutics Inc The simple moving average for the last 20 days is -0.34% for ESPR stock, with a simple moving average of -13.24% for the last 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral.” The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
BofA Securities gave a rating of “Underperform” to ESPR, setting the target price at $2.50 in the report published on June 20th of the previous year.
ESPR Trading at -14.17% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.78% of loss for the given period.
Volatility was left at 6.13%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares sank -11.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.09% lower at present.
During the last 5 trading sessions, ESPR rose by +6.15%, which changed the moving average for the period of 200-days by -6.86% in comparison to the 20-day moving average, which settled at $1.9065. In addition, Esperion Therapeutics Inc saw -13.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who proposed sale 239 shares at the price of $1.87 back on Feb 19 ’25. After this action, Warren Eric now owns shares of Esperion Therapeutics Inc, valued at $446 using the latest closing price.
Halladay Benjamin, the Officer of Esperion Therapeutics Inc, proposed sale 11 shares at $1.86 during a trade that took place back on Feb 19 ’25, which means that Halladay Benjamin is holding shares at $20 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.29. The total capital return value is set at 0.11.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -0.73. The interest coverage ratio of the stock is 0.28.
Currently, EBITDA for the company is -150.11 million with net debt to EBITDA at -4.31. When we switch over and look at the enterprise to sales, we see a ratio of 1.69. The receivables turnover for the company is 4.36for trailing twelve months and the total asset turnover is 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
In a nutshell, Esperion Therapeutics Inc (ESPR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
